Chemistry:Imetelstat

From HandWiki
Short description: Experimental cancer drug
Imetelstat
Imetelstat.svg
Imetelstat 3D.png
Clinical data
Other namesGRN163L
ATC code
Legal status
Legal status
  • Experimental
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC148H210N68O53P13S13
Molar mass4610
3D model (JSmol)

Imetelstat (development code GRN163L) is an experimental anticancer drug.[1] The first telomerase inhibitor to enter clinical trials,[2] As of early 2023, it was in Phase 2/3 trials for various cancer types.[which?][2]

Chemically, imetelstat is a synthetic conjugate consisting of three parts: GRN163, a thio phosphoramide oligonucleotide, and a palmitoyl lipid group.[2] GRN163 is the pharmacological component with telomerase inhibition. The palmitic acid moiety is conjugated via a phosphothioate linkage to the backbone of the antisense oligonucleotide. Telomere shortening and lower cell viability are observed after inhibition of telomerase activity in vitro. IC50 values ranged from 50 to 200nM for 10 different pancreatic cell lines. [3]

References

  1. "Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells". PLOS ONE 9 (1): e85155. 2014. doi:10.1371/journal.pone.0085155. PMID 24409321. Bibcode2014PLoSO...985155B. 
  2. 2.0 2.1 2.2 "Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials". Current Topics in Medicinal Chemistry 20 (6): 433–457. 2020. doi:10.2174/1568026620666200102104930. PMID 31894749. 
  3. "Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma". Hepatology 42 (5): 1127–36. November 2005. doi:10.1002/hep.20822. PMID 16114043.